Clinical Trial Update: Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases [Phase 2]

View source ↗

Summary

A Phase 2 trial update describing a novel combination of intrathecal pemetrexed with high-dose furmonertinib and bevacizumab for EGFR-mutant non-small cell lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Carcinomatosis
• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• Furmonertinib (furmonertinib)
• Pemetrexed (Alimta) (pemetrexed)

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING